CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

2024

5 Dec 2024, 15:30
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
Data from the trial is expected to be shared in 2025
3 Dec 2024, 07:00
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment
13 Nov 2024, 09:00
Hansa Biopharma to Attend Jefferies London Healthcare Conference
30 Oct 2024, 09:00
Hansa Biopharma to Attend Truist Securities BioPharma Symposium
17 Oct 2024, 07:00 | Regulatory
Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results
Q3 2024 marks highest ever in-market quarterly sales performance and fourth consecutive quarter of strong sales performance
7 Oct 2024, 10:00
Hansa Biopharma’s HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial
3 Oct 2024, 07:00
Hansa Biopharma to host Q3 2024 interim results conference call
5 Sep 2024, 11:00
Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Load more

E-mail

Sign up to receive updates on the latest company news and filings

Choose type

I consent to Hansa Biopharma handling my personal data. See our Privacy Policy for information about how we handle personal data.

Thank you. You will get an e-mail message to activate your subscription.